Sleep Disorders in Europe: Economic Impact & Costs (Germany Ranked 4th)

Berlin – The economic toll of sleepless nights is substantial, with a fresh European study revealing that sleep disorders cost Germany an estimated €106 billion annually. This figure underscores a growing public health concern, as nearly one in three Europeans now grapple with conditions ranging from insomnia to sleep apnea. The financial burden extends beyond direct healthcare costs, encompassing significant losses in productivity and workforce participation. As awareness grows, experts are calling for increased investment in sleep health initiatives, preventative care, and improved diagnostic tools.

The study, published in the European Journal of Neurology, examined the economic and epidemiological impact of five common sleep disorders – obstructive sleep apnea, chronic insomnia, restless legs syndrome, narcolepsy, and REM sleep behavior disorder – across 47 European countries. Researchers found that Germany ranks fourth among 30 high-income nations in terms of per capita costs associated with sleep disorders, exceeding €1,200 annually per person. This places a significant strain on the nation’s healthcare system and economy, highlighting the urgent need for comprehensive solutions. The findings, released in early March 2026, coincide with World Sleep Day, a global event dedicated to raising awareness about the importance of sleep.

The Hidden Costs of Lost Sleep

While the €106 billion figure is alarming, researchers caution that the true economic impact of sleep disorders in Germany may be even higher. The initial calculation doesn’t fully account for “presenteeism” – the phenomenon of employees being physically present at perform but functioning at reduced capacity due to sleep deprivation – or the impact of undiagnosed, subclinical sleep disturbances. The long-term health consequences of chronic sleep loss, such as increased risk of cardiovascular disease, diabetes, and mental health disorders, contribute to indirect costs that are tough to quantify. According to the study, these factors suggest the actual economic burden could be substantially larger than currently estimated.

“Our modeling study illuminates the economic implications of sleep disorders in Germany and other European countries,” explains Luisa Welter of the University of Duisburg-Essen, a German co-author of the research. “To mitigate the health and economic consequences, awareness of the importance of sleep health should be raised, and prevention, diagnosis, and care should be improved. To act based on evidence in the future, research in this area should also be promoted.” This call for increased research funding reflects a growing recognition that sleep disorders are not merely lifestyle issues but serious medical conditions with far-reaching consequences.

Prevalence Across Europe and the French Model

The European study reveals a widespread problem, with approximately one in three adults across the continent affected by sleep disorders. Specifically, 31% of European adults suffer from obstructive sleep apnea, insomnia, and restless legs syndrome, according to research cited in Der Standard. This translates to hundreds of billions of euros in annual costs across the region. The researchers emphasize that these figures underscore the need for a paradigm shift in how sleep health is prioritized within public health systems.

France has emerged as a leader in addressing this issue, implementing comprehensive measures to promote sleep health. The French Ministry of Health, Family, Solidarity and People with Disabilities launched an interministerial roadmap in 2025-2026 focused on improving sleep quality, as detailed in a document available on sante.gouv.fr. This roadmap includes initiatives aimed at raising public awareness, improving access to diagnosis and treatment, and promoting healthy sleep habits. The success of the French model could serve as a blueprint for other European nations seeking to address the growing crisis of sleep deprivation.

Understanding the Types of Sleep Disorders

Sleep disorders encompass a wide range of conditions, each with its own unique characteristics and treatment approaches. Obstructive sleep apnea (OSA), characterized by repeated interruptions in breathing during sleep, is a particularly prevalent and serious condition. Left untreated, OSA can lead to cardiovascular problems, stroke, and daytime fatigue. Chronic insomnia, defined as difficulty falling asleep or staying asleep for at least three months, can significantly impair daily functioning and quality of life. Restless legs syndrome (RLS), a neurological disorder causing an irresistible urge to move the legs, often disrupts sleep and can be debilitating. Narcolepsy, a rare neurological disorder, causes excessive daytime sleepiness and sudden attacks of sleep. Finally, REM sleep behavior disorder (RBD) involves acting out dreams during REM sleep, potentially leading to injury to oneself or a bed partner.

The Role of Idorsia Pharmaceuticals

Pharmaceutical companies like Idorsia Pharmaceuticals are actively involved in developing innovative treatments for sleep disorders. Idorsia, a Swiss-based biopharmaceutical company with a German subsidiary, is focused on researching and developing medications to address unmet needs in the field of sleep medicine. The company’s pipeline includes potential therapies for chronic insomnia, aiming to revolutionize the treatment of this widespread condition. Idorsia’s commitment to innovation reflects a broader trend within the pharmaceutical industry towards recognizing the importance of sleep health and investing in solutions to improve sleep quality for millions of people.

Looking Ahead: Prioritizing Sleep Health

The findings of this European study serve as a wake-up call for policymakers, healthcare professionals, and individuals alike. Prioritizing sleep health is not simply a matter of personal well-being; it is an economic imperative. Investing in preventative care, improving access to diagnosis and treatment, and promoting public awareness are crucial steps towards mitigating the significant financial and health consequences of sleep disorders. Further research is needed to fully understand the complex interplay between sleep, health, and economic productivity. The German government, along with other European nations, is now under pressure to adopt comprehensive strategies to address this growing public health challenge.

The next key development to watch is the potential implementation of new sleep health initiatives in Germany, following the example set by France. Further data on the economic impact of specific sleep disorders within Germany is also expected to be released in late 2026. The European Sleep Research Society will also be hosting a major conference in October 2026, where the latest research findings will be presented and discussed.

What are your thoughts on the economic impact of sleep disorders? Share your experiences and insights in the comments below. Don’t forget to share this article with your network to raise awareness about the importance of sleep health.